Pfizer will present the RSV vaccine results to a CDC advisory committee, which will decide when and how often the shot should be administered in the U.S.
Pfizer's results are a first glimpse at its vaccine's durability in protecting against RSV, which causes mild symptoms similar to a cold in most people but more severe infections in older adults and children.
But the 18-month data also suggests Pfizer's shot is still generally protective against RSV after one year. Annaliesa Anderson, head of Pfizer's vaccine research and development, told CNBC that the company is "very encouraged" by data from the phase three clinical trial. "As with most vaccines, you're really looking for an impact against more severe disease that causes higher levels of mortality, morbidity and health-care associated contact," Anderson told CNBC. "To be able to see high efficacy carrying on is very important to us, and we think it's going to provide people comfort as they take the vaccine."
Nigeria Latest News, Nigeria Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Episode 3: RSV Infections in Patients Receiving Bone Marrow TransplantRSV infection before or after bone marrow transplantation or CAR T-cell therapy can be challenging to manage. Tune in to hear experts Drs Forest Arnold and Melody Smith discuss.
Read more »
CDC to investigate swine flu virus behind woman's death in BrazilThe CDC plans to probe samples collected from a fatal influenza infection in Brazil, after investigators discovered the death was caused by an H1N1 variant spreading in pigs.
Read more »
Outgoing CDC director says resignation spurred by sense of accomplishment and exhaustionThe outgoing head of the Centers for Disease Control and Prevention said her reasons for stepping down were complicated, driven in part by a desire to take a break from the frenetic pace of the job during a pandemic
Read more »
Outgoing CDC director says resignation spurred by sense of accomplishment and exhaustionThe outgoing head of the Centers for Disease Control and Prevention said her reasons for stepping down were complicated, driven in part by a desire to take a break from the frenetic pace of the job during a pandemic. Dr. Rochelle Walensky surprised many in public health circles last month by announcing her departure after just two years and five months. In an interview with the Associated Press, Walensky said she decided to step down because she felt she had shepherded the agency through the pandemic and needed a break from the intense schedule she’s kept the last few years.
Read more »
Outgoing CDC director says resignation spurred by sense of accomplishment and exhaustionThe outgoing head of the Centers for Disease Control and Prevention said her reasons for stepping down were complicated, driven in part by a desire to take a break from the frenetic pace of the job during a pandemic.
Read more »
Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head startThe FDA's strain selection puts Pfizer, Moderna and Novavax on track to deliver updated coronavirus shots in time for the fall.
Read more »